The Fédération Equestre Internationale (FEI) has announced that four endurance horses have tested positive for prohibited substances under the federation’s Equine Anti-Doping and Controlled Medication Regulations.

The following athletes have been provisionally suspended from the date of notification until the FEI Tribunal renders its decisions; The horses have been provisionally suspended for two months:

Horse: Flor Del Caribe
Person Responsible: Federica Rossi (ARG)
Event: CEI3* 160 – Abu Dhabi, Al Wathba (UAE)
Date of Event: Feb. 10, 2018
Prohibited Substances: GW1516 (an anabolic substance that, according to the FEI’s Equine Prohibited Substance Database [EPSD], increases exercise capacity, metabolism in skeletal muscles to burn fat, and muscle mass) and GW1516 sulphone
Date of notification: March 19, 2018

Horse: Bolota De Alcantara
Person Responsible: Rodrigo Picão Abreu (POR)
Event: CEI2* 120 Reguengos de Monsaraz (POR)
Date of Event: Feb. 17, 2018
Prohibited Substance: O-desmethyl venlafaxine (an antidepressant agent, categorized as a serotonin and noradrenaline re-uptake inhibitor; in humans it is used to treat major depression and generalized anxiety disorders, according to the EPSD)
Date of notification: March 19, 2018

Horse: Tina La Boheme
Person Responsible: Mohammed Ahmed Al Owais (UAE)
Event: CSI2* – Abu Dhabi (UAE)
Date of Event: Feb. 14-17, 2018
Prohibited Substance: Diisopropylamine (a vasodilator used in the treatment of peripheral and cerebral vascular disorders)
Date of notification: March 19, 2018

Horse: Sohair Des Bruyere
Person Responsible: Elizaveta Minina (RUS)
Event: CEI2* 120 – Doha, Mesaieed (QAT)
Date of Event: Jan. 20, 2018
Prohibited Substance: Testosterone (a naturally occurring steroid hormone produced primarily in the testes and, to a lesser degree, the ovaries which has anabolic effects)
Date of notification: March 5, 2018

Details on these cases are available on the FEI website at and

Final Decision

Additionally, the FEI Tribunal has issued its final decision in the case against Italian jumping rider Giacomo Basso after his mount Cenerado tested positive for stanozolol and ketoprofen.

Stanozol is an anabolic steroid and a banned substance under the under the federation’s Equine Anti-Doping and Controlled Medication Regulations.; “although they have been used with (bonafide) medical intent in horses, anabolic steroids have also been used illicitly in equine sports to attempt to improve performance, mainly due to their effect of promoting muscular development,” the EPSD states. “The use of anabolic steroids long term, or at high doses carries significant risks.”

Ketoprofen is a controlled substance. The non-steroidal anti-inflammatory drug has antipyretic (fever-reducing) and analgesic (pain-relieving) properties. The EPSD says the drug’s detection time is estimated with 96 hours (4 days) after intravenous administration.

Samples taken from Cenerado at the CSI3* at Gorla Minore (ITA) on March 12, 2017, returned positive for the two substances and the athlete was provisionally suspended on April 5, 2017. The FEI provisionally suspended Cenerado for two months.

In its final decision, the FEI Tribunal imposed a two-year suspension on the athlete, starting from the date of sample collection and running through to March 11, 2019. The FEI Tribunal also imposed a fine of CHF 4,000 and ordered the athlete to contribute CHF 2,500 towards the costs of the judicial procedure, plus the cost of “B sample” analysis.

The final decision is available on the FEI website at Basso has 21 days from the date of notification (March 23, 2018) to appeal the decision to the Court of Arbitration for Sport.